

DAFTAR PUSTAKA

- [1] R. Paulmurugan, "Introduction to cancer biology," *Mol. Imaging Probes Cancer Res.*, pp. 3–27, 2012, doi: 10.1142/9789814293686_0001.
- [2] M. DEWI, "Sebaran Kanker di Indonesia, Riset Kesehatan Dasar 2007," *Indones. J. Cancer*, vol. 11, no. 1, pp. 1–8, 2017, doi: 10.33371/ijoc.v11i1.494.
- [3] WHO, "Breast cancer." <https://www.who.int/news-room/fact-sheets/detail/breast-cancer> (accessed Apr. 05, 2022).
- [4] H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries," *CA. Cancer J. Clin.*, vol. 71, no. 3, pp. 209–249, 2021, doi: 10.3322/caac.21660.
- [5] Y. Vaidya, P. Vaidya, and T. Vaidya, "Ductal Carcinoma In Situ of the Breast," *Indian J. Surg.*, vol. 77, no. 2, pp. 141–146, 2015, doi: 10.1007/s12262-013-0987-0.
- [6] S. T. Lutz, J. Jones, and E. Chow, "Role of radiation therapy in palliative care of the patient with cancer," *J. Clin. Oncol.*, vol. 32, no. 26, pp. 2913–2919, 2014, doi: 10.1200/JCO.2014.55.1143.
- [7] E. J. Hall, "Intensity-modulated radiation therapy, protons, and the risk of second cancers," *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 65, no. 1, pp. 1–7, 2006, doi: 10.1016/j.ijrobp.2006.01.027.
- [8] E. Senkus-Konefka and J. Jassem, "Complications of breast-cancer radiotherapy," *Clin. Oncol.*, vol. 18, no. 3, pp. 229–235, 2006, doi: 10.1016/j.clon.2005.11.004.
- [9] A. Lechner, "Particle interactions with matter," *Cern Yellow Reports Sch. Proc.*, vol. 5, no. March, pp. 47–68, 2018, doi: 10.23730/CYRSP-2018-005.47.
- [10] Y. Yonekura, H. Tsujii, J. W. Hopewell, P. Ortiz López, J. M. Cosset, H. Paganetti, A. Montelius, D. Schardt, B. Jones, and T. Nakamura, "Radiological protection in ion beam radiotherapy: practical guidance for clinical use of new technology," *Ann. ICRP*, vol. 45, pp. 138–147, 2015, doi: 10.1177/0146645316630708.
- [11] C. Nilsson and A. Valachis, "The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: A meta-analysis of observational studies," *Radiother. Oncol.*, vol. 114, no. 1, pp. 50–55, 2015, doi: 10.1016/j.radonc.2015.01.001.
- [12] R. Yosi and A. Sari, "Analisis Sifat-Sifat Pion Dalam Reaksi Inti Dalam



- Terapi Pion,” *Pros. Semin. Nas. “Meneguhkan Peran Penelit. dan Pengabdi. Kpd. Masy. dalam Memuliakan Martabat Manusia”* , pp. 1028–1036, 2016.
- [13] P. H. Fowler, “The Possibility of Therapeutic Applications of Beams of Negative π -Mesons,” *Nature*, vol. 189, no. 4764, pp. 524–528, 1961.
 - [14] C. Richman, “The physics of cancer therapy with negative pions,” *Med. Phys.*, vol. 8, no. 3, pp. 273–291, 1981, doi: 10.1118/1.594868.
 - [15] T. Sato, K. Niita, N. Matsuda, S. Hashimoto, Y. Iwamoto, T. Furuta, S. Noda, T. Ogawa, H. Iwase, H. Nakashima, T. Fukahori, K. Okumura, T. Kai, S. Chiba, and L. Sihver, “Overview of particle and heavy ion transport code system PHITS,” *Ann. Nucl. Energy*, vol. 82, pp. 110–115, 2015, doi: 10.1016/j.anucene.2014.08.023.
 - [16] L. Rosen, “Possibilities and Advantages of Using Negative Pions in Radiotherapy,” *Nucl. Appl.*, vol. 5, no. 6, pp. 379–388, 1968, doi: 10.13182/nt68-a27964.
 - [17] D. K. Bewley, “Pions and Heavy Ions in Radiotherapy,” *Nature*, vol. 237, pp. 17–19, 1972.
 - [18] R. W. Harrison and D. E. Lobb, “A Negative Pion Beam Transport Channel for Radiobiology and Radiation Therapy at TRIUMF,” pp. 1029–1031, 1973.
 - [19] G. K. Y. Lam, G. B. Goodman, R. W. Harrison, L. D. Skarsgard, and R. O. Kornelsen, “Cancer radiotherapy using negative pi-mesons,” *Nucl. Inst. Methods Phys. Res. B*, vol. 10–11, no. PART 2, pp. 1096–1101, 1985, doi: 10.1016/0168-583X(85)90179-X.
 - [20] G. Schmitt, C. F. Von Essen, R. Greiner, and H. Blattmann, “Review of the SIN and Los Alamos Pion Trials,” *Radiat. Res.*, vol. 104, no. 2 II, 1985, doi: 10.2307/3576657.
 - [21] H. Blattmann, “Treatment Planning and Optimization for Pion Therapy,” *Boron Neutron Capture Ther.*, pp. 129–141, 1992, doi: 10.1007/978-1-4615-3408-2_15.
 - [22] J. Haussmann, S. Corradini, and C. Nestle-Kraemling, “Recent advances in radiotherapy of breast cancer,” *Radiat. Oncol.*, vol. 15, no. 71, pp. 1–10, 2020, doi: 10.1186/s13014-020-01501-x.
 - [23] D. Griffiths, *Introduction to Elementary Particles*. New York: John Wiley and Sons, 1987.
 - [24] H. Yukawa, S. Sakata, and M. Taketani, “On the Interaction of Elementary Particles. III,” *Prog. Theor. Phys. Suppl.*, vol. 1, no. Received, pp. 24–45, 1955, doi: 10.1143/ptps.1.24.
 - [25] C. L. Vieira and A. A. P. Videira, “Carried by History: Cesar Lattes, Nuclear Emulsions, and the Discovery of the Pi-meson,” *Phys. Perspect.*, vol. 16, no.



- 1, pp. 3–36, 2014, doi: 10.1007/s00016-014-0128-6.
- [26] K. A. Olive, “Neutral Pi Meson,” 2014. [Online]. Available: <https://pdg.lbl.gov/2014/listings/rpp2014-list-pi-zero.pdf>
- [27] K. A. Olive, “Positive and Negative Pi Meson,” 2014. [Online]. Available: <http://pdg.lbl.gov/2014/listings/rpp2014-list-pi-plus-minus.pdf>
- [28] V. P. Bond, “Negative pions: their possible use in radiotherapy,” in *52nd Annual Meeting of the American Radium Society*, New York, 1971, pp. 9–26.
- [29] D. Hovarth, K. A. Aniol, F. Entezami, D. F. Measday, A. J. Noble, S. Stanislaus, and C. J. Virtue, “Experimental study of pion capture by hydrogen bound in molecules,” *Phys. Rev. A*, vol. 41, no. 11, 1990.
- [30] M. R. Raju, “Negative Pion Beams for Radiotherapy,” pp. 33–62, 1971.
- [31] P. L. Petti and A. J. Lennox, “Hadronic Radiotherapy,” *Annu. Rev. Nucl. Part. Sci.*, vol. 44, pp. 155–197, 1994.
- [32] M. R. Raju, “Negative pions in radiotherapy: A brief review,” *Eur. J. Cancer*, vol. 10, no. 4, pp. 211–215, 1974, doi: 10.1016/0014-2964(74)90177-7.
- [33] S. B. Curtis and M. R. Raju, “A Calculation of the Physical Characteristics of Negative Pion Beams Energy-Loss Distribution and Bragg Curves,” *Lawrence Berkeley Natl. Lab.*, 1967.
- [34] D. R. Perry, “Physical aspects of a radiobiological pion beam,” University of Surrey, 1975.
- [35] M. R. Raju, H. I. Amols, J. F. Dicello, J. Howard, J. T. Lyman, A. M. Koehler, R. Graves, and J. B. Smathers, “A heavy particle comparative study. Part I: Depth-dose distributions,” *Br. J. Radiol.*, vol. 51, no. 609, pp. 699–703, 1978, doi: 10.1259/0007-1285-51-609-699.
- [36] D. A. Pistenma, G. C. Li, P. Fessenden, K. White, and M. A. Bagshaw, “Treatment planning for negative pi-meson radiation therapy: Simultaneous multi-port irradiation with the Stanford Medical Pion Generator (SMPG),” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 3, no. C, pp. 315–323, 1977, doi: 10.1016/0360-3016(77)90270-X.
- [37] J. M. Sala and M. M. Kilgerman, “Clinical experience with negative pi mesons and other high-LET radiations,” *Adv. Med. Oncol.*, vol. 6, pp. 215–221, 1979.
- [38] H. Ellis and V. Mahadevan, “Anatomy and physiology of the breast,” *Surg. (United Kingdom)*, vol. 31, no. 1, pp. 11–14, 2013, doi: 10.1016/j.mpsur.2012.10.018.
- [39] R. P. Tamin, “Mengenal Anatomi Payudara Wanita.”



<https://www.alodokter.com/mengenal-anatomi-payudara-wanita> (accessed Dec. 12, 2022).

- [40] A. R. Tanjung and E. N. Hadi, "Female Students' Perception on Breast Cancer Detection Using Breast Self Examination (SADARI) Method," *Proc. Int. Conf. Appl. Sci. Heal.*, no. 3, pp. 369–373, 2018.
- [41] I. Yulianti and S. Henry, "Faktor Resiko Ca. Mamae," *J. Kesehat. Masy.*, vol. 4, pp. 401–409, 2016.
- [42] M. Kamińska, T. Ciszewski, K. Łopacka-Szatan, P. Miotła, and E. Starosławska, "Breast cancer risk factors," *Prz. Menopauzalny*, vol. 14, no. 3, pp. 196–202, 2015, doi: 10.5114/pm.2015.54346.
- [43] A. B. R. Arafah and H. B. Notobroto, "Faktor Yang Berhubungan Dengan Perilaku Ibu Rumah Tangga Melakukan Pemeriksaan Payudara Sendiri (Sadari)," *Indones. J. Public Heal.*, vol. 12, no. 2, p. 143, 2018, doi: 10.20473/ijph.v12i2.2017.143-153.
- [44] M. Islam, "Genetics in breast cancer and treatment strategy: A current scenario," *Int. J. Med.*, vol. 5, no. 2, p. 223, 2017, doi: 10.14419/ijm.v5i2.8077.
- [45] A. D. Ahmad, "Hormone Replacement Therapy pada Wanita Menopause Meningkatkan Risiko Terjadinya Ductal Carsinoma In Situ," *Majority*, vol. 8, no. 2, pp. 205–208, 2019.
- [46] J. Koh and M. J. Kim, "Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage," *Korean J. Radiol.*, vol. 20, no. 1, pp. 69–82, 2019, doi: 10.3348/kjr.2018.0231.
- [47] M. Ramli, "Update Breast Cancer Management," *J. Fak. Kedokt. Andalas*, vol. 38, pp. 28–52, 2015.
- [48] L. J. Solin, "Management of Ductal Carcinoma In Situ (DCIS) of the Breast: Present Approaches and Future Directions," *Curr. Oncol. Rep.*, vol. 21, no. 4, pp. 19–26, 2019, doi: 10.1007/s11912-019-0777-3.
- [49] S. Avril, R. F. Muzic, D. Plecha, B. J. Traughber, S. Vinayak, and N. Avril, "18F-FDG PET/CT for monitoring of treatment response in breast cancer," *J. Nucl. Med.*, vol. 57, no. 2, pp. 34S–39S, 2016, doi: 10.2967/jnumed.115.157875.
- [50] G. Mitchell, "The rationale for fractionation in radiotherapy," *Clin. J. Oncol. Nurs.*, vol. 17, no. 4, pp. 412–417, 2013, doi: 10.1188/13.CJON.412-417.
- [51] F. Basyid and K. Adi, "Segmentasi Citra Medis Untuk Pengenalan Objek Kanker Menggunakan Metode Active Contour," *Youngster Phys. J.*, vol. 3, no. 3, pp. 209–216, 2014.
- [52] T. Pavel, "Feasibility of magnetic resonance imaging-based radiation therapy for brain tumour treatment," Aalto University, 2017.



- [53] “cyclotron | Description, History, & Facts | Britannica.” <https://www.britannica.com/technology/cyclotron> (accessed Aug. 04, 2022).
- [54] S. Saminto, S. F. Permana, and A. Susanto, “Rancang Bangun Perangkat Instrumentasi Kendali Pada Sistem Pendingin Siklotron DECY-13 MeV,” in *Prosiding Pertemuan dan Presentasi Ilmiah Penelitian Dasar Ilmu Pengetahuan dan Teknologi Nuklir*, BATAN, 2017, pp. 167–176.
- [55] R. S. Darmawan and S. Santosa, “Perancangan Komponen Dee Siklotron Proton 13 MeV,” pp. 65–71, 2011.
- [56] T. P. Wangler, *Linear accelerators*. 2007. doi: 10.1007/978-3-540-47648-1_3364.
- [57] R. A. Serway, *Principles of Physics: A Calculus-Based Text*, 4th Editio. Brooks Cole, 2005.
- [58] I. Bylinskii and M. K. Craddock, “The TRIUMF 500 MeV cyclotron: The driver accelerator,” *Hyperfine Interact.*, vol. 225, no. 1–3, pp. 9–16, 2014, doi: 10.1007/s10751-013-0878-6.
- [59] I. Sekachev, I. Bylinskii, A. Koveshnikov, I. Slobodov, and D. Yosifov, “Triumf Cyclotron Vacuum System Upgrade and Operational Experience,” *Proc. PAC09*, no. May, pp. 9–11, 2009.
- [60] A. Mutzke, G. Bandelow, and R. Schneider, “Sputtering of mixed materials of beryllium and tungsten by hydrogen and helium,” *J. Nucl. Mater.*, vol. 467, pp. 413–417, 2015, doi: 10.1016/j.jnucmat.2015.05.052.
- [61] M. R. Raju, *Heavy Particle Radiotherapy*, vol. 39, no. 6. New York: Academic Press, 1980.
- [62] Z. Liang, K. Liu, B. Qin, W. Chen, X. Liu, D. Li, and Y. Xiong, “Design and optimization of an energy degrader with a multi-wedge scheme based on Geant4,” *Nucl. Instruments Methods Phys. Res. Sect. A Accel. Spectrometers, Detect. Assoc. Equip.*, vol. 890, no. 11375068, pp. 112–118, 2018, doi: 10.1016/j.nima.2018.01.073.
- [63] H. Fritz-Niggli, “Radiobiological evaluation of the suitability of negative pions in tumor therapy; facts and theories,” *Radiat. Environ. Biophys.*, vol. 17, no. 1, pp. 47–65, 1979, doi: 10.1007/BF01323120.
- [64] R. Greiner, H. Blattmann, P. Thum, P. Bösiger, A. Coray, R. Kann, T. Lahtinen, H. Reinhardt, C. F. von Essen, and A. Zimmermann, “Anaplastic astrocytoma and glioblastoma: pion irradiation with the dynamic conformation technique at the Swiss Institute for Nuclear Research (SIN),” *Radiother. Oncol.*, vol. 17, no. 1, pp. 37–46, 1990, doi: 10.1016/0167-8140(90)90047-Z.
- [65] M. R. Raju and A. J. van der Kogel, “Radiobiology of pions in comparison with other heavy particles,” *Radiother. Oncol.*, vol. 17, no. 1, pp. 1–5, 1990,



doi: 10.1016/0167-8140(90)90042-U.

- [66] D. T. L. Jones, "Overview of hadron therapy: Rationales, present status and future prospects," *Radiochim. Acta*, vol. 89, no. 4–5, pp. 235–244, 2001, doi: 10.1524/ract.2001.89.4-5.235.
- [67] M. M. Kligerman, W. C. Black, J. M. Yuhas, R. C. Doberneck, J. N. Bradbury, and C. A. Kelsey, "Current status of clinical pion radiotherapy," *Radiology*, vol. 125, no. 2, pp. 489–492, 1977, doi: 10.1148/125.2.489.
- [68] K. R. Shortt, "The Absolute Dosimetry of Negative Pions," The University of British Columbia, 1979.
- [69] M. R. Raju, H. I. Amols, E. Bain, S. G. Carpenter, R. A. Cox, and J. B. Robertson, "OER and RBE for negative pion beams of different peak widths," *Br. J. Radiol.*, vol. 52, no. 618, pp. 494–498, 1979, doi: 10.1259/0007-1285-52-618-494.
- [70] JAEA, "Ver. 3.27 User's Manual," 2022.
- [71] A. F. Bielajew, *Fundamentals of the Monte Carlo method for neutral and charged particle transport*. University of Michigan, 2020.
- [72] L. L. Carter and E. D. Cashwell, "Particle-Transport Simulation with the Monte Carlo Method," 1975. doi: 10.2172/4167844.
- [73] JAEA, "Update log of PHITS." <https://phits.jaea.go.jp/rirekie.html> (accessed Jun. 06, 2023).
- [74] D. C. Hagerman, "Operating Results on the 800 MeV Proton Linac at the Los Alamos Scientific Laboratory," pp. 905–909, 1973.
- [75] C. Lukaski, "Methods for assessment of body composition: tradisional and new.," *Am. J. Clin. Nutr.*, vol. 46, no. February, pp. 537–556, 1987.
- [76] G. D. Kerr, J. M. L. Hwang, and R. M. Jones, "A Mathematical Model of a Phantom Developed for Use in Calculations of Radiation Dose to the Body and Major Internal Organs of a Japanese Adult," *J. Radiat. Res.*, vol. 17, no. 4, pp. 211–229, 1976, doi: 10.1269/jrr.17.211.
- [77] D. R. White, R. V. Griffith, and I. J. Wilson, "Photon, Electron, Proton and Neutron Interaction Data for Body Tissues," *ICRU Rep. 46*, 1992.
- [78] D. B. Siwi, "Analisis Dosis di Organ Kritis pada Terapi Globlastoma dengan Boron Neutron Capture Therapy menggunakan Metode Simulasi MCNP5," Universitas Gadjah Mada, 2013.
- [79] Pacific Northwest National Laboratory, "Compendium of Material Composition Data for Radiation Transport Modeling," Washington DC, 2011.
- [80] M. Ilham, "Analisis Dosis dan Waktu Iradiasi Terapi Proton pada Kanker



Serviks Menggunakan PHITS,” Universitas Gadjah Mada, 2022. Skripsi.

- [81] L. Z. Braunstein, E. F. Gillespie, L. Hong, A. Xu, S. F. Bakhoun, J. Cuaron, B. Mueller, B. McCormick, O. Cahlon, S. Powell, and A. J. Khan, “Breast Radiation Therapy Under COVID-19 Pandemic Resource Constraints—Approaches to Defer or Shorten Treatment From a Comprehensive Cancer Center in the United States,” *Adv. Radiat. Oncol.*, vol. 5, no. 4, pp. 582–588, 2020, doi: 10.1016/j.adro.2020.03.013.
- [82] H. Ko, J. S. Chang, J. Y. Moon, W. H. Lee, C. Shah, J. S. Shim, M. C. Han, J. G. Baek, R. H. Park, Y. B. Kim, and J. S. Kim, “Dosimetric Comparison of Radiation Techniques for Comprehensive Regional Nodal Radiation Therapy for Left-Sided Breast Cancer: A Treatment Planning Study,” *Front. Oncol.*, vol. 11, no. April, pp. 1–9, 2021, doi: 10.3389/fonc.2021.645328.
- [83] The Royal College of Radiologists, “Postoperative radiotherapy for breast cancer: UK consensus statements,” *Clinical Oncology*. <https://www.rcr.ac.uk/clinical-oncology/service-delivery/postoperative-radiotherapy-breast-cancer-uk-consensus-statements> (accessed Mar. 05, 2023).
- [84] S. S. Lo, A. Sahgal, E. L. Chang, N. A. Mayr, B. S. Teh, Z. Huang, T. E. Schefter, M. Yao, M. Machtay, B. J. Slotman, and R. D. Timmerman, “Serious Complications Associated with Stereotactic Ablative Radiotherapy and Strategies to Mitigate the Risk,” *Clin. Oncol.*, vol. 25, no. 6, pp. 378–387, 2013, doi: 10.1016/j.clon.2013.01.003.
- [85] A. Sahgal, J. H. Chang, L. Ma, L. B. Marks, M. T. Milano, P. Medin, A. Niemierko, S. G. Soltys, W. A. Tomé, C. S. Wong, E. Yorke, J. Grimm, and A. Jackson, *Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy*, vol. 110, no. 1. Elsevier Inc., 2021. doi: 10.1016/j.ijrobp.2019.09.038.
- [86] R. E. Drzymala, R. Mohan, L. Brewster, J. Chu, M. Goitein, W. Harms, and M. Urie, “Dose-volume histograms,” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 21, no. 1, pp. 71–78, 1991, doi: 10.1016/0360-3016(91)90168-4.

